INREBIC Drug Patent Profile

When do Inrebic patents expire, and what generic alternatives are available?

Inrebic is a drug marketed by Bristol-myers and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and nineteen patent family members in forty-two countries.

The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this compound. Additional details are available on the fedratinib hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Inrebic

Inrebic was eligible for patent challenges on August 16, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 16, 2031. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for INREBIC

International Patents:	119
US Patents:	5
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INREBIC

Paragraph IV (Patent) Challenges for INREBIC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INREBIC	Capsules	fedratinib hydrochloride	100 mg	212327	1	2023-08-16

US Patents and Regulatory Information for INREBIC

INREBIC is protected by five US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 7,528,143.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol-myers	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes	10,391,094		Y
Bristol-myers	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes	7,825,246			Y
Bristol-myers	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes	8,138,199

International Patents for INREBIC

When does loss-of-exclusivity occur for INREBIC?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Denmark

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Netherlands

New Zealand

Norway

Portugal

Russian Federation

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INREBIC around the world.

Country	Patent Number	Title	Estimated Expiration
Ukraine	109411
Ukraine	99899	БИАРИЛ-МЕТА-ПИРИМИДИНОВЫЕ ИНГИБИТОРЫ КИНАЗ;БІАРИЛ-МЕТА-ПІРИМІДИНОВІ ІНГІБІТОРИ КІНАЗ (BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES)
World Intellectual Property Organization (WIPO)	2012060847

Supplementary Protection Certificates for INREBIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1951684	14/2021	Austria		PRODUCT NAME: FEDRATINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON ODER EIN PHARMAZEUTISCH ANNEHMBARES HYDRAT DAVON, INSBESONDERE FEDRATINIB-DIHYDROCHLORID-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/20/1514 (MITTEILUNG) 20210209
1951684	2021C/513	Belgium		PRODUCT NAME: FEDRATINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, OU UN HYDRATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE DICHLORHYDRATE DE FEDRATINIB MONOHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/20/1514 20210209
1951684	767	Finland

Analysis of INREBIC: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

INREBIC (mainly known as fedratinib) is an oral kinase inhibitor developed by 母Janssen Pharmaceuticals (Johnson & Johnson) for myeloproliferative neoplasms, notably myelofibrosis. Since FDA approval in August 2019, the drug presents specific opportunities and challenges. Its market penetration, competitive stance, and financial outlook reflect broader trends in hematology drug markets, regulatory environment, and innovation in targeted therapies. This report evaluates INREBIC’s investment prospects, analyzing current market dynamics, revenue projections, competitive landscape, and strategic considerations.

---

1. Introduction to INREBIC

Attribute	Details
Generic Name	Fedratinib
Indication	Intermediate- or high-risk myelofibrosis (MF)
Formulation	Oral, 100 mg and 200 mg capsules
Approval Date	August 2019 (FDA)
Developer	Janssen Pharmaceuticals (Johnson & Johnson)
Orphan Drug Designation	Yes

Mechanism of Action:
Fedratinib selectively inhibits JAK2 and FLT3 kinases, reducing abnormal cell proliferation associated with MF and related disorders.

Market approval was contingent on resolving prior regulatory concerns over cases of Wernicke’s encephalopathy linked to hematologic toxicity, which Janssen addressed through risk management programs.

---

2. Current Market Status and Revenue

Year	Revenue (USD millions)	Market Share in MF	Key Notes
2019	$10.7	5%	Post-approval launch phase, limited market penetration.
2020	$15.1	8%	Slight growth, entry of competing agents.
2021	$22.4	12%	Increasing awareness, expanded prescriptions.
2022	$28.9	15%	Gained approval in additional regions, ongoing competition.

Source: Evaluate Pharma, 2023.

---

3. Market Dynamics and Competitive Environment

3.1. Target Market Overview

Disease Condition	Prevalence	Estimated Market Size (USD)	Growth Factors
Myelofibrosis	2.7 per 100,000 globally	$4.3 billion (estimated in hematology drugs)	Rising diagnosis rates, orphan drug incentives
Polycythemia Vera & Essential Thrombocythemia	Additional MF subtypes	Significant overlap, expanding potential

Note: The global prevalence is estimated at approximately 34,000 cases—underserved, with unmet medical needs.

3.2. Key Competitors

Drug	Mechanism	Market Share (2022)	Approvals & Status	Remarks
Ruxolitinib (Jakafi)	JAK1/JAK2 inhibitor	50%	FDA-approved 2011	First-line therapy for MF
Pacritinib	JAK2/FLT3 inhibitor	Limited	FDA pending; breakthrough status	Developing niche for thrombocytopenic patients
Momelotinib	JAK1/2 and ACVR1 inhibition	Clinical stage	Phase III trials	Addresses anemia, fatigue

Analysis: INREBIC's niche is as a second-line or alternative treatment, particularly for patients intolerant or resistant to JAK2 inhibitors like Jakafi.

---

4. Financial Trajectory and Investment Outlook

4.1. Revenue Projections (2023–2028)

Year	Revenue Estimate (USD millions)	Assumptions	Notes
2023	$35–40	Steady growth, expanding indications	Enhanced physician awareness, new regional approvals
2024	$50–60	Increased prescriptions, potential label expansion	Potential entry for early-line combination therapy
2025	$70–85	Broader global coverage, potential new indications	Competitive pressures, price negotiations
2026	$100+	Dominance in niche segments, possible biosimilar entry	Market maturation, ongoing clinical data development

Note: Revenue will depend on regulatory decisions, competitive advances, and market acceptance.

4.2. Investment Considerations

Aspect	Analysis
R&D Investment	Historically low post-approval, enabling profit focus
Patent Status	Patent expirations could occur post-2030; current exclusivity in key regions
Pricing Strategy	Premium pricing justified by orphan status and efficacy
Market Expansion	Potential in Asia-Pacific, emerging markets

---

5. Regulatory and Policy Environment

Region	Status	Policy Implications	Remarks
US	Approved via FDA	Orphan Drug Incentives, Risk Management	Favorable, stable environment
EU	EMA approval granted	Market access, pricing negotiations	Regulations mirror US but with price controls
Asia-Pacific	Registrations ongoing	Varying regulatory stringency	Opportunity for growth
India/SE Asia	Limited approvals	Cost-sensitive markets, biosimilar threats	Market entry contingent on pricing strategies

---

6. Strategic Opportunities and Risks

6.1. Opportunities

• Indication Expansion: Potential for indications in myelodysplastic syndromes or leukemia.
• Combination Therapy: Synergistic use with other agents such as immunotherapies.
• Global Market Penetration: Particularly in Asia-Pacific countries with rising prevalence.
• Orphan Designation Benefits: Extended exclusivities and subsidies.

6.2. Risks

• Competitive Pressure: Jakafi dominance limits market share growth.
• Regulatory Challenges: Any safety concerns, like encephalopathy, can impede approvals.
• Pricing Pressures: Reimbursement challenges, especially in public healthcare systems.
• Pipeline Uncertainty: Lack of substantial pipeline drugs diminishes long-term prospects.

---

7. Comparative Analysis and Benchmarking

Product	Indication	Market Share	Launch Year	Revenue (USD millions, 2022)	Status
Fedratinib (INREBIC)	Myelofibrosis	15%	2019	$29	Growing niche drug
Ruxolitinib	Myelofibrosis	50%	2011	$2,200+	Market leader
Pacritinib	MF	Low (clinical phase)	N/A	N/A	Competitive threat

Note: INREBIC's positioning as a second-line agent sustains modest but steady revenue.

---

8. FAQs

Q1: What factors influence the future growth of INREBIC?
A1: The key drivers include expansion into new geographic regions, indication expansion, clinical trial success for combination therapies, and overcoming competitive limitations from established drugs like Jakafi.

Q2: How does patent expiry risk impact investment in INREBIC?
A2: Patent cliffs could open the market to biosimilars or generics post-2030, reducing pricing power and revenues. Current patent protections in major jurisdictions mitigate this in the short to medium term.

Q3: What regulatory challenges could affect INREBIC’s trajectory?
A3: Safety concerns related to prior Wernicke’s encephalopathy reports, or any unforeseen adverse events, could delay approvals, restrict indications, or lead to market withdrawals.

Q4: How does the competitive landscape affect INREBIC’s profitability?
A4: Dominance by Jakafi limits market share growth; however, INREBIC’s unique mechanism offers opportunities for niche markets, especially in patients resistant to JAK inhibitors.

Q5: What strategic moves should Janssen consider to maximize INREBIC’s value?
A5: Focus on global expansion, explore combination regimens, accelerate indications for other hematological conditions, and optimize pricing and reimbursement negotiations.

---

Key Takeaways

• Market Position: INREBIC holds a modest but growing position as a second-line therapy for myelofibrosis, with revenues trending up (~$30 million in 2022).

• Growth Opportunities: Expansion into new regions, indication expansion, and combination therapies represent strategic paths to boost revenues.

• Competitive Dynamics: Ruxolitinib’s dominance constrains INREBIC’s market share; differentiation relies on safety profiles and niche targeting.

• Regulatory and Patent Outlook: Current regulatory environment is favorable; patent protections extend into the early 2030s.

• Investment Outlook: Moderate growth potential with manageable risks; best suited for specialized hematology portfolios emphasizing orphan drugs.

---

References

1. Evaluate Pharma. (2023). Global Oncology Market Data.
2. Johnson & Johnson. (2019). FDA Approval Announcement for Fedratinib.
3. FDA. (2019). Labeling and Risk Management for INREBIC.
4. ClinicalTrials.gov. (2023). Ongoing Trials for Fedratinib in Hematology.
5. IQVIA. (2022). Global Hematology Drug Sales and Market Share Data.